LQDA vs TXG: fair value comparison
Liquidia Corporation and 10x Genomics, Inc. · Updated 2026-10-19
LQDA's estimate rests on a sector-average multiple, which TickrTrends does not publish as a verdict. TXG has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. Within Healthcare, TXG currently ranks higher by quality score. TXG carries the stronger quality grade.
| LQDA | TXG | |
|---|---|---|
| Verdict | Awaiting full valuation | No estimate yet |
| Last price | $34.35 | $69.86 |
| 12-month range | $22.38–$91.03 | $12.44–$97.74 |
| Rank by discount to fair value | — | — |
| Rank by quality score | #47 of 301 Healthcare | #45 of 301 Healthcare |
| Quality grade | B | A |
| Leverage | Moderate | Low |
| Margin trend | Expanding | Stable |
| Revenue growth | — | Declining |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Mixed | Mixed |
| 52-week position | The bottom quarter | The upper-middle quarter |
Full single-stock breakdowns: LQDA fair value analysis · TXG fair value analysis